PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner

Published:2021 Issue: Volume:28 Page:100379
ISSN:2468-2942
Container-title:Cancer Treatment and Research Communications
language:en
Short-container-title:Cancer Treatment and Research Communications

Author:

He Honghong,Shi Liyan,Meng Dan,Zhou Huijun,Ma Jingshu,Wu Yixian,Wu Yanshi,Gu Yanzheng,Xie Wei,Zhang Jing,Zhu Yibei

Funder

Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference45 articles.

1. Cancer immunotherapy;McNutt;Science,2013

2. PD-1/PD-L1 pathway: basic biology and role in cancer immunotherapy;Salmaninejad;J Cell Physiol,2019

3. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2;Yokosuka;J Exp Med,2012

4. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent;Kamphorst;Science,2017

5. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition;Hui;Science,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the multifaceted antitumor effects of interleukin 33;Frontiers in Immunology;2024-05-31

2. Upgrading Melanoma Treatment: Promising Immunotherapies Combinations in the Preclinical Mouse Model;Current Cancer Therapy Reviews;2023-10-12

3. The alarmin interleukin-33 promotes the expansion and preserves the stemness of Tcf-1+ CD8+ T cells in chronic viral infection;Immunity;2023-04

4. Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer;International Journal of Molecular Sciences;2022-08-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3